Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.
BACKGROUND: We report on a follow-up clinical and serological investigation of 274 children who received seasonal influenza vaccine (trivalent inactivated vaccine [TIV]) 1 year after receipt of either AS03(B)-adjuvanted subunit or whole virus monovalent A(H1N1)pdm09 vaccine and describe the antibody...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2014
|
| _version_ | 1797087005475078144 |
|---|---|
| author | Hoschler, K Andrews, N Faust, SN Finn, A Pollard, A Snape, M Walker, W Zambon, M Miller, E |
| author_facet | Hoschler, K Andrews, N Faust, SN Finn, A Pollard, A Snape, M Walker, W Zambon, M Miller, E |
| author_sort | Hoschler, K |
| collection | OXFORD |
| description | BACKGROUND: We report on a follow-up clinical and serological investigation of 274 children who received seasonal influenza vaccine (trivalent inactivated vaccine [TIV]) 1 year after receipt of either AS03(B)-adjuvanted subunit or whole virus monovalent A(H1N1)pdm09 vaccine and describe the antibody responses to the H3N2 A/Perth/16/2009 and B/Brisbane/60/2008 components of TIV. METHODS: Vaccine responses were analyzed using hemagglutination inhibition (HAI) assays. In children aged <3 years, previous receipt of adjuvanted vaccine resulted in higher HAI antibody responses to H3N2 and B strains compared with nonadjuvanted vaccine (fold change 16.8 vs 4.3 for H3N2 and 7.0 vs 1.6 for B). In children aged >3 years, responses to the H3 and B components of TIV were similar between vaccine groups. Sera taken before and after the pandemic vaccine were also analyzed by HAI using A/Perth/16/2009 virus. This analysis showed that 11.1% of children receiving the AS03(B)-adjuvanted vaccine but only 1.4% in the nonadjuvanted group had a 4-fold rise to A/Perth/16/2009. CONCLUSION: AS03B-adjuvanted A(H1N1)pdm09 influenza vaccine generates a cross-reactive antibody response to H3N2 in children and enhances responses to heterologous subtypes in children aged <3 years 1 year later. |
| first_indexed | 2024-03-07T02:29:58Z |
| format | Journal article |
| id | oxford-uuid:a6e69735-8157-492e-9361-974b3bf2804d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:29:58Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:a6e69735-8157-492e-9361-974b3bf2804d2022-03-27T02:50:45ZAdministration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a6e69735-8157-492e-9361-974b3bf2804dEnglishSymplectic Elements at Oxford2014Hoschler, KAndrews, NFaust, SNFinn, APollard, ASnape, MWalker, WZambon, MMiller, EBACKGROUND: We report on a follow-up clinical and serological investigation of 274 children who received seasonal influenza vaccine (trivalent inactivated vaccine [TIV]) 1 year after receipt of either AS03(B)-adjuvanted subunit or whole virus monovalent A(H1N1)pdm09 vaccine and describe the antibody responses to the H3N2 A/Perth/16/2009 and B/Brisbane/60/2008 components of TIV. METHODS: Vaccine responses were analyzed using hemagglutination inhibition (HAI) assays. In children aged <3 years, previous receipt of adjuvanted vaccine resulted in higher HAI antibody responses to H3N2 and B strains compared with nonadjuvanted vaccine (fold change 16.8 vs 4.3 for H3N2 and 7.0 vs 1.6 for B). In children aged >3 years, responses to the H3 and B components of TIV were similar between vaccine groups. Sera taken before and after the pandemic vaccine were also analyzed by HAI using A/Perth/16/2009 virus. This analysis showed that 11.1% of children receiving the AS03(B)-adjuvanted vaccine but only 1.4% in the nonadjuvanted group had a 4-fold rise to A/Perth/16/2009. CONCLUSION: AS03B-adjuvanted A(H1N1)pdm09 influenza vaccine generates a cross-reactive antibody response to H3N2 in children and enhances responses to heterologous subtypes in children aged <3 years 1 year later. |
| spellingShingle | Hoschler, K Andrews, N Faust, SN Finn, A Pollard, A Snape, M Walker, W Zambon, M Miller, E Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later. |
| title | Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later. |
| title_full | Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later. |
| title_fullStr | Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later. |
| title_full_unstemmed | Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later. |
| title_short | Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later. |
| title_sort | administration of as03b adjuvanted a h1n1 pdm09 vaccine in children aged lt 3 years enhances antibody response to h3 and b viruses following a single dose of trivalent vaccine one year later |
| work_keys_str_mv | AT hoschlerk administrationofas03badjuvantedah1n1pdm09vaccineinchildrenagedlt3yearsenhancesantibodyresponsetoh3andbvirusesfollowingasingledoseoftrivalentvaccineoneyearlater AT andrewsn administrationofas03badjuvantedah1n1pdm09vaccineinchildrenagedlt3yearsenhancesantibodyresponsetoh3andbvirusesfollowingasingledoseoftrivalentvaccineoneyearlater AT faustsn administrationofas03badjuvantedah1n1pdm09vaccineinchildrenagedlt3yearsenhancesantibodyresponsetoh3andbvirusesfollowingasingledoseoftrivalentvaccineoneyearlater AT finna administrationofas03badjuvantedah1n1pdm09vaccineinchildrenagedlt3yearsenhancesantibodyresponsetoh3andbvirusesfollowingasingledoseoftrivalentvaccineoneyearlater AT pollarda administrationofas03badjuvantedah1n1pdm09vaccineinchildrenagedlt3yearsenhancesantibodyresponsetoh3andbvirusesfollowingasingledoseoftrivalentvaccineoneyearlater AT snapem administrationofas03badjuvantedah1n1pdm09vaccineinchildrenagedlt3yearsenhancesantibodyresponsetoh3andbvirusesfollowingasingledoseoftrivalentvaccineoneyearlater AT walkerw administrationofas03badjuvantedah1n1pdm09vaccineinchildrenagedlt3yearsenhancesantibodyresponsetoh3andbvirusesfollowingasingledoseoftrivalentvaccineoneyearlater AT zambonm administrationofas03badjuvantedah1n1pdm09vaccineinchildrenagedlt3yearsenhancesantibodyresponsetoh3andbvirusesfollowingasingledoseoftrivalentvaccineoneyearlater AT millere administrationofas03badjuvantedah1n1pdm09vaccineinchildrenagedlt3yearsenhancesantibodyresponsetoh3andbvirusesfollowingasingledoseoftrivalentvaccineoneyearlater |